Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer

Targeting 17q23 amplicon to overcome the resistance to anti-HER2 therapy in HER2+ breast cancer

The 17q23 amplicon containing the WIP1 oncogene is frequently amplified in HER2+ breast cancer. Here they find MIR21 to be present in WIP1-containing amplicons, and report nanoparticle based co-delivery of WIP1 and miR-21 inhibitors to be effective in trastuzumab-resistant HER2+ breast cancer.

Bibliographic Details
Main Authors: Yunhua Liu, Jiangsheng Xu, Hyun Ho Choi, Cecil Han, Yuanzhang Fang, Yujing Li, Kevin Van der Jeught, Hanchen Xu, Lu Zhang, Michael Frieden, Lifei Wang, Haniyeh Eyvani, Yifan Sun, Gang Zhao, Yuntian Zhang, Sheng Liu, Jun Wan, Cheng Huang, Guang Ji, Xiongbin Lu, Xiaoming He, Xinna Zhang
Format: Article
Language:English
Published: Nature Portfolio 2018-11-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-018-07264-0

Internet

https://doi.org/10.1038/s41467-018-07264-0

Similar Items